Connor, Clark & Lunn Investment Management (CC&L)’s Sage Therapeutics SAGE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-187,048
| Closed | -$1.49M | – | 1665 |
|
|
2025
Q1 | $1.49M | Buy |
187,048
+17,991
| +11% | +$143K | 0.01% | 814 |
|
|
2024
Q4 | $918K | Buy |
169,057
+103,495
| +158% | +$562K | ﹤0.01% | 965 |
|
|
2024
Q3 | $473K | Buy |
+65,562
| New | +$473K | ﹤0.01% | 1112 |
|
|
2023
Q3 | – | Sell |
-93,329
| Closed | -$4.39M | – | 1518 |
|
|
2023
Q2 | $4.39M | Sell |
93,329
-15,293
| -14% | -$719K | 0.02% | 426 |
|
|
2023
Q1 | $4.56M | Sell |
108,622
-7,043
| -6% | -$296K | 0.02% | 388 |
|
|
2022
Q4 | $4.41M | Buy |
115,665
+56,482
| +95% | +$2.15M | 0.03% | 380 |
|
|
2022
Q3 | $2.32M | Buy |
59,183
+5,540
| +10% | +$217K | 0.02% | 467 |
|
|
2022
Q2 | $1.73M | Buy |
53,643
+11,140
| +26% | +$360K | 0.01% | 499 |
|
|
2022
Q1 | $1.41M | Sell |
42,503
-30,874
| -42% | -$1.02M | 0.01% | 591 |
|
|
2021
Q4 | $3.12M | Buy |
73,377
+19,544
| +36% | +$831K | 0.02% | 432 |
|
|
2021
Q3 | $2.39M | Buy |
+53,833
| New | +$2.39M | 0.01% | 489 |
|
|
2021
Q2 | – | Sell |
-10,596
| Closed | -$793K | – | 1088 |
|
|
2021
Q1 | $793K | Buy |
10,596
+5,904
| +126% | +$442K | ﹤0.01% | 727 |
|
|
2020
Q4 | $406K | Buy |
+4,692
| New | +$406K | ﹤0.01% | 749 |
|